MGTA Annual Cash & Cash Equivalents
$57.63 M
-$74.02 M-56.23%
31 December 2022
Summary:
As of January 20, 2025, MGTA annual cash & cash equivalents is $57.63 million, with the most recent change of -$74.02 million (-56.23%) on December 31, 2022. During the last 3 years, it has fallen by -$7.45 million (-11.44%).MGTA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA Quarterly Cash And Cash Equivalents
$62.63 M
+$14.11 M+29.08%
30 June 2023
Summary:
As of January 20, 2025, MGTA quarterly cash and cash equivalents is $62.63 million, with the most recent change of +$14.11 million (+29.08%) on June 30, 2023. Over the past year, it has increased by +$7.80 million (+14.23%).MGTA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.2% | +14.2% |
| 3 y3 years | -11.4% | -54.0% |
| 5 y5 years | +12.1% | -63.9% |
MGTA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time | -56.2% | -63.9% |
Magenta Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| June 2023 | - | $62.63 M(+29.1%) |
| Mar 2023 | - | $48.52 M(-15.8%) |
| Dec 2022 | $57.63 M(-56.2%) | $57.63 M(-2.4%) |
| Sept 2022 | - | $59.03 M(+7.7%) |
| June 2022 | - | $54.83 M(-23.6%) |
| Mar 2022 | - | $71.77 M(-45.5%) |
| Dec 2021 | $131.65 M(+126.4%) | $131.65 M(-16.4%) |
| Sept 2021 | - | $157.54 M(+1.6%) |
| June 2021 | - | $155.03 M(+214.5%) |
| Mar 2021 | - | $49.29 M(-15.2%) |
| Dec 2020 | $58.15 M | $58.15 M(-59.0%) |
| Sept 2020 | - | $141.68 M(+4.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2020 | - | $136.29 M(+81.9%) |
| Mar 2020 | - | $74.93 M(+15.2%) |
| Dec 2019 | $65.07 M(+11.5%) | $65.07 M(-23.9%) |
| Sept 2019 | - | $85.51 M(+158.2%) |
| June 2019 | - | $33.11 M(+6.0%) |
| Mar 2019 | - | $31.24 M(-46.5%) |
| Dec 2018 | $58.34 M(+13.5%) | $58.34 M(-63.5%) |
| Sept 2018 | - | $159.67 M(-7.9%) |
| June 2018 | - | $173.43 M(+318.3%) |
| Mar 2018 | - | $41.46 M(-19.3%) |
| Dec 2017 | $51.40 M(+1039.0%) | $51.40 M |
| Dec 2016 | $4.51 M | - |
FAQ
- What is Magenta Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Magenta Therapeutics?
- What is Magenta Therapeutics annual cash & cash equivalents year-on-year change?
- What is Magenta Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Magenta Therapeutics?
- What is Magenta Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Magenta Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of MGTA is $57.63 M
What is the all time high annual cash & cash equivalents for Magenta Therapeutics?
Magenta Therapeutics all-time high annual cash & cash equivalents is $131.65 M
What is Magenta Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, MGTA annual cash & cash equivalents has changed by -$74.02 M (-56.23%)
What is Magenta Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MGTA is $62.63 M
What is the all time high quarterly cash and cash equivalents for Magenta Therapeutics?
Magenta Therapeutics all-time high quarterly cash and cash equivalents is $173.43 M
What is Magenta Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, MGTA quarterly cash and cash equivalents has changed by +$7.80 M (+14.23%)